GLP-1 Daily: Ozempic & Wegovy News

South African regulators admit they're on the back foot against bulk-compounded and black-market weight-loss jabs, and Belgium refuses to reimburse Mounjaro for obesity. A JAMA Network Open study finds about half of early Wegovy pill starters were new to GLP-1s. In this episode: 1. SA regulators struggle to control illegal weight-loss jabs — Daily Maverick https://www.dailymaverick.co.za/article/2026-10-23-sas-regulators-are-struggling-to-keep-up-with-black-market-weight-loss-jabs/?dm_campaign=inform&dm_medium=card-link&dm_position=1&dm_source=blocks-grid 2. Belgium Rejects Reimbursement for Mounjaro in Obesity Treatment | NAVLIN DAILY — NAVLIN DAILY https://www.navlindaily.com/article/32278/belgium-rejects-reimbursement-for-mounjaro-in-obesity-treatment 3. Oral Semaglutide Uptake Near Injectable Levels Within 3 ... — AJMC https://www.ajmc.com/view/oral-semaglutide-uptake-near-injectable-levels-within-3-months Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

Mass General Brigham confirms affected employee plans will stop covering GLP-1s for weight loss on January 1, 2027, and British MPs say the NHS plan for Mounjaro reaches only about 6% of eligible people. CBS News lab-tested vials sold as retatrutide and found one held no peptide at all, plus bacteria. In this episode: 1. EXCLUSIVE: Mass General Helped Give the World GLP-1. Now Its Own Benefits Are Pulling Back Obesity Drug Coverage | On The Pen — On The Pen GLP-1 News https://onthepen.com/news/exclusive-mass-general-helped-give 2. Give more people weight loss jabs on the NHS, say MPs - BBC News — BBC News https://www.bbc.co.uk/news/articles/cm4g1pkwxdqwo 3. We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying." - CBS News — Adam Yamaguchi Correspondent https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys. In this episode: 1. Obese Woman Ordered to Arbitrate Claims vs. Anthem Over Zepbound Denial - MyNewsLA.com — Mynewsla https://mynewsla.com/orange-county/2026/10/20/obese-woman-ordered-to-arbitrate-claims-vs-anthem-over-zepbound-denial/ 2. STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction — STAT https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/?utm_campaign=rss 3. Oral Semaglutide Kidney Outcomes in SOUL | PeptideMethods — PeptideMethods https://peptidemethods.com/blog/oral-semaglutide-kidney-soul-trial Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an expected FDA decision. In this episode: 1. Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients — Medical Daily https://www.medicaldaily.com/houston-rx-fda-483-compounded-tirzepatide-recall-sterility-480121 2. GLP-1 analogues and GIP/GLP-1 dual analogues: risks associated with misuse and off-label use for weight loss | FAMHP — FAMHP https://www.faag.be/en/news/glp_1_analogues_and_gipglp_1_dual_analogues_risks_associated_with_misuse_and_off_label_use_for 3. CagriSema Weight Loss in Women | Novo Nordisk U.S. — Novo Nordisk U.S. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo pill. In this episode: 1. FDA Flags Chinese GLP-1 Ingredient Suppliers — Kalbir Talwar https://www.briefs.co/news/fda-flags-two-chinese-makers-of-compounded-glp-1-ingredients/ 2. Prescription Denials For GLP-1 Receptor Agonists Across Commercial, Medicare, And Medicaid Coverage, 2018–2024 | Health Affairs Scholar | Oxford Academic — Jia, Miaoqing, Levy, Joseph F, McGinty, Emma E, Tummalapalli, Sri Lekha, Zhang, Yongkang https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag284/8922286 3. EMA CHMP Backs Orforglipron (Foundayo): Non-Peptide GLP-1 EU Approval Implications — BSR — Biotech Research https://biotechresearch.co.uk/intelligence/emas-chmp-backs-orforglipron-for-the-eu-what-the-non-peptide-glp-1-opinion-means-for-the-research-landscape Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]